DUBLIN--(BUSINESS WIRE)--The "Autoimmune Disease Diagnosis Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
The global autoimmune disease diagnosis market is expected to grow from $3.38 billion in 2020 to $4.15 billion in 2021 at a compound annual growth rate (CAGR) of 22.8%. The market is expected to reach $5.75 billion in 2025 at a CAGR of 8%.
Major players in the autoimmune disease diagnosis market are Thermo Fisher Scientific, Siemens Healthineers, Abbott, Danaher, Bio-Rad Laboratories, Trinity Biotech, Hycor Biomedical, Euroimmun AG, and Aesku Group GMBH & CO. KG.
The market for autoimmune disease diagnosis consists of sales of diagnostic assay kits, reagents, consumables and instruments used for the diagnosis of autoimmune diseases. Autoimmune diseases are the diseases in which the production of antibodies takes place in the body which attack and destroy healthy cells in the body. These include Crohn's disease, rheumatoid arthritis, Hashimoto's disease, multiple sclerosis, Grave's disease, psoriasis, coeliac disease, type 1 diabetes, lupus and inflammatory bowel syndrome, and are diagnosed by immunological tests.
The autoimmune disease diagnosis market covered in this report is segmented by product into consumables & assay kits, instruments. It is also segmented by test type into routine laboratory tests, autoantibodies tests, immunologic tests, other tests and by end-user into clinical laboratories, hospitals, other end-users.
The high cost of diagnostic tests is a major challenge for the growth of the autoimmune disease diagnosis market. According to a survey by the National Adrenal Diseases Foundation (NADF), the cost for initial diagnosis of Addison's disease is $1,680 per patient and according to the reports of Vasculitis Foundation of America, vasculitis affects 1 in 20 Americans and the total cost for vasculitis patient per year is $9.7 billion.
According to the estimations of The National Institutes of Allergy and Infectious Diseases (NIAID), the annual cost of treating an autoimmune disease in the US is greater than $100 billion and says that annual direct and indirect cost to treat rheumatoid arthritis in the US is $10.9 billion and $8.4 billion respectively. The high cost of diagnosis is increasing the cost burdens on the patients impacting the growth of the autoimmune disease diagnosis market
A high incidence of autoimmune diseases contributed to the growth of the autoimmune disease diagnosis market. The percentage of the adult population diagnosed with autoimmune diseases in 2019 across countries was 7% in the US, 6% in Europe, 5% in China, 3% each in Brazil and Russia and Japan 2%.
According to a report by Connect Immune Research, the incidence of autoimmune diseases in the UK is increasing, which ranges between 3% and 9% year-on-year. In these, different autoimmune conditions such as rheumatoid arthritis 7%, type 1 diabetes 6.3%, multiple sclerosis 3.7%, coeliac disease 4-9% cases are increasing every year and the number of people in the UK with at least one autoimmune condition is 4 million. Therefore, increasing incidence of autoimmune diseases across the globe is driving the autoimmune disease diagnosis market.
Biosensors and nano biosensors for rapid detection is a novel tool for the detection of antibodies in the autoimmune disease diagnosis market. They are highly preferred because of low cost, high sensitivity, simplicity to use, multiplexing abilities and rapid diagnosis.
Besides measuring the quantity of antibodies in human blood serum with extremely high sensitivity, it also quantifies the activity of antibodies as the assay employs portable optical label-free biosensors based on the spectral correlation interferometry. This point of care technology gives a more integrated, informative, timely and precise diagnosis of autoimmune diseases when compared to the conventional ones.
Key Topics Covered:
1. Executive Summary
2. Autoimmune Disease Diagnosis Market Characteristics
3. Autoimmune Disease Diagnosis Market Trends and Strategies
4. Impact Of COVID-19 On Autoimmune Disease Diagnosis
5. Autoimmune Disease Diagnosis Market Size and Growth
5.1. Global Autoimmune Disease Diagnosis Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of the Market
5.1.2. Restraints On the Market
5.2. Global Autoimmune Disease Diagnosis Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of the Market
5.2.2. Restraints On the Market
6. Autoimmune Disease Diagnosis Market Segmentation
6.1. Global Autoimmune Disease Diagnosis Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
- Consumables & Assay Kits
6.2. Global Autoimmune Disease Diagnosis Market, Segmentation by Test Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
- Routine Laboratory Tests
- Autoantibodies Tests
- Immunologic Tests
- Other Tests
6.3. Global Autoimmune Disease Diagnosis Market, Segmentation By End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
- Clinical Laboratories
- Other End Users
7. Autoimmune Disease Diagnosis Market Regional and Country Analysis
7.1. Global Autoimmune Disease Diagnosis Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Autoimmune Disease Diagnosis Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
- Thermo Fisher Scientific
- Siemens Healthineers
- Bio-Rad Laboratories
- Trinity Biotech
- HYCOR Biomedical
- EUROIMMUN AG
- AESKU GROUP GMBH & CO. KG
- F. Hoffmann-La Roche Ltd
- Beckman Coulter
- SQI Diagnostics
- Quest Diagnostics
- INOVA Diagnostics
- BioMerieux SA
- Hemagen Diagnostics
- Haemonetics Corporation
- Fresenius Kabi
- Asahi Kasei Kuraray Medical Co. Ltd
- Terumo BCT
- HTG Molecular Diagnostics
- Seramun Diagnostica GmbH
- Exagen Inc.
- Cambridge Life Sciences Limited
- A. Menarini Diagnostics s.r.l
- ORGENTEC Diagnostika
For more information about this report visit https://www.researchandmarkets.com/r/fwn4ce